The science of living longer means little until it reaches real people. This is the central thesis of the August Wellness Index Report, published by Wellness Eternal, which spotlights the discipline of translational longevity—the work of closing the gap between laboratory discoveries and clinical application. As longevity research accelerates, the report argues, the ability to deliver these advances to patients is where the true impact lies.
The report identifies three key signals indicating progress in this field. First, cell science is moving from proof of concept to real clinical delivery. Decades of research in transplantation and cell therapy are transitioning from specialized centers into broader clinical practice, reversing—rather than merely managing—the drivers of disease and aging. Second, evidence is emerging as the bridge from research to practice. As longevity claims multiply, the field rewards those who can separate what is proven from what is merely promising, making evidence-based guidance invaluable for clinicians, executives, and policymakers. Third, clinical strategy and systems are proving essential to scaling care. Even the most effective therapy fails if the healthcare system cannot deliver it safely and consistently, emphasizing the need for operational rigor and smarter care models.
The report features three experts who represent distinct vantage points in translational longevity. Dr. Camillo Ricordi, a professor at the University of Miami, anchors the first signal with his work in translational cell therapy. Dr. David Barzilai, a Harvard Medical School lecturer and longevity medicine physician, embodies the second signal, known for making complex science accessible and actionable. Dr. Suzie Robertson, a clinical pharmacist and healthcare strategist at Matrix Biologics, exemplifies the third signal, bridging clinical excellence with innovation to improve patient safety and care delivery models.
These efforts will converge at the Translational Longevity Summit, hosted by Boston BioLife and the Healthspan Action Coalition, scheduled for October 7-11 at the Harvard Enterprise Research Campus in Boston. The summit is led by Joseph Krieger, president and founder of Boston BioLife, and Bernard Siegel, founder of the Healthspan Action Coalition. Krieger has spent over 25 years in healthcare and life sciences, focusing on streamlining translational medicine by uniting laboratory discovery, clinical practice, and community impact. Siegel, a patient advocate and cancer survivor, has been instrumental in advancing the stem cell and regenerative medicine ecosystem, conceptualizing and co-chairing twenty World Stem Cell Summits.
"The future of longevity is translational. The breakthroughs are real, but they only matter when they reach people. That is the work these three share, and the reason the field is converging on Boston this October," said Lindsay O'Neill-O'Keefe, founder of Wellness Eternal and creator of the Wellness Index Report. "Discovery is only half the job. Delivery is the rest. The future of longevity is not just discovered. It is delivered."
The Wellness Index Report is an independent, practitioner-led research platform published monthly by Wellness Eternal. It evaluates wellness providers, technologies, and protocols through a four-step process: expert nomination, customer and patient feedback, clinical review, and ongoing performance tracking. The report is distributed across major media outlets and reaches a global audience, providing visibility to solutions that meet its integrity-first standard. The full August report is available at wellnessindexreport.com.
